UK pharma: 25 years of innovation and controversy
Whitefriars’ Ketan Patel discusses what investors need to consider when investing in the pharmaceutical sector
PA Future Committee
-
-
Time to say goodbye
Knowing when engagement has reached the end of the road, by Castlefield’s Ita McMahon
-
Has trust in ESG claims hit rock bottom?
The FCA has provided a window of opportunity to turn perceptions around, writes the AIC’s Nick Britton
-
We urgently need a just transition in the mining sector
The supply-demand imbalance for critical minerals poses a risk to the global energy transition, says RLAM’s Hamilton-Claxton
-
Over-boarding galore further besets open-ended property funds
Open-ended property funds can learn a lot from their REIT counterparts, writes Quilter Cheviot’s Gemma Woodward
-
Sustainable seas: The role investors can play in marine conservation
Investing in sustainable ocean-based initiatives can help protect one of our planet’s most vital resources, writes Amy Clarke
-
Investor capital can help feed a changing food system
Nordea’s Eric Pedersen discusses the challenges the food industry faces and how engagement is working
-
Leading change: How are fund managers walking the walk?
Those not flexing their stewardship muscles are getting called out, writes Jake Moeller
-
What to expect in SFDR overhaul
Simplicity and precision should be the highest priorities, says CFA Institute’s Chris Fidler
-
Momentous momentum: Will sustainable investors find some welcome relief?
In a narrow, momentum-led market, managers may feel pressured to chase mega caps where sustainability or corporate behaviour is questionable
-
COP29: Delivering on climate finance?
The summit, to be held in Baku in November, has attracted controversy on diversity, human rights and fossil fuels
-
Financing transition: The role of public/private partnerships in accelerating the UK’s green transition
The Investment Association’s Paul Scaping shares his thoughts on the role of private finance under the Labour government